Clinical trial
Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma
NCT00190424 · Assistance Publique - Hôpitaux de Paris, Other · Completed
Key facts
| NCT number | NCT00190424 |
|---|---|
| Title | Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma |
| Official title | Multicentric Randomized Phase 2. Immunotherapy With CpG-ODN in Malignant Glioblastoma |
| Lead sponsor | Assistance Publique - Hôpitaux de Paris, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Glioblastoma |
| Intervention type | Drug |
| Interventions | CpG-ODN |
| Enrollment | 80 |
| Start date | Sep 1, 2005 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2010 |
| First posted | Sep 19, 2005 |
| Last update posted | Dec 13, 2012 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: